ATM Mutations and radio-sensitivity : a review of molecular pathology and cancer susceptibility by Mezzomo, Lisiane Cervieri et al.
 
 
International Journal of Pharmacy and Biological Sciences-IJPBSTM (2020) 10 (2): 229-237 
Online ISSN: 2230-7605, Print ISSN: 2321-3272 





DOI: https://doi.org/10.21276/ijpbs.2020.10.2.28                                                           Lisiane Cervieri Mezzomo* et al 
                                                                                          www.ijpbs.com  or www.ijpbsonline.com 
229 
ATM Mutations and Radio-sensitivity:  
A Review of Molecular Pathology and 
Cancer Susceptibility 
  
Lisiane Cervieri Mezzomo1, Silvia Maria Spalding1, Luciane 
Noal Calil1, Renata Pereira Limberger1 and Adelina Mezzari1 
1Analysis department, Faculty of Pharmacy, Federal University of Rio Grande 
do Sul, Brazil. 
 
          Received: 10 Jan 2020 / Accepted: 18 March 2020 / Published online: 01 April 2020   
   *Corresponding Author Email: lisimezzomo@gmail.com 




Hereditary mutations of genes involved in DNA repair have resulted in increased susceptibility 
to a variety of cancers. Mutations in ataxia telangiectasia mutated (ATM) gene result in an 
autossomal recessive disorder ataxia telangiectasia syndrome (AT), which manifests with 
greater predisposition to various types of cancer, radiotherapy resistance and adverse 
prognosis. Therefore, patients with AT and their cells are radiosensitive, mainly because ATM 
protein kinase is a regulator of DNA damage identification and cell cycle control in response to 
ionizing radiation. Blood relatives of AT can also carry a pathogenic ATM mutation, which 
presents similar or even other risks (not yet completely described), although apparently healthy. 
Due to the unusual phenotype of radiosensitive cells in ATM patients, it has been the focus of 
numerous studies in the past two decades. The efficiency of radiotherapy treatment among 
ATM patients has been questioned due to its toxic effect on normal tissue. As certain ATM 
signaling provided valuable information about the response to DNA damage and cancer, but the 
understanding of the role of ATM in radio sensitivity is still incipient and, therefore, the 
molecular determinants of the clinical response are poorly understood so far. On the face of 
these considerations, this work presents a review of the normal structure and function of the 
ATM with compilation of the current literature on the risk of radio sensitivity and malignancy 
among patients with mutations in the ATM.  
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Activation of checkpoint arrest and DNA repair are 
necessary to maintain genomic integrity during DNA 
replication. Defective DNA repair is seen in cancer 
and results in genomic instability and the 
accumulation of other genetic abnormalities (1, 2). 
Thus, cancers with mutations in the genes that 
encode proteins involved in DNA repair may be more 
sensitive to treatments, inducing DNA damage or 
inhibiting complementary DNA repair mechanisms 
(3). 
Hereditary mutations of genes involved in DNA 
repair, such as ataxia telangiectasia mutated (ATM), 
are causative of ataxia-telangiectasia syndrome (AT), 
a rare autosomal recessive systemic disorder first 
described more than 60 years ago(4), which result in 
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considerably increased susceptibility to a variety of 
malignancies, ranging from 10% to 20% (5, 6). Cancer 
types risk includes lymphoid, gastric, breast, central 
nervous system, skin, and others. In adition, 
progressive cerebellar ataxia, immunological defects, 
insulin-resistant diabetes and radiosensitivity can 
occur in this patient characterized by biallelic 
mutations in the ATM gene. Besides that, a large 
number of mutations (more than 600) can occur in 
the ATM coding and noncoding regions (7), and the 
patient's response varies depending on the type of 
mutation. ATM protein kinase is involved in many 
cellular functions, including response to DNA 
damage, control of the cell cycle checkpoint, 
apoptosis (8) oxidative stress and mitochondrial 
metabolism (9). It integrates the cellular response to 
damage by phosphorylation of the main proteins 
involved in cell cycle regulation and DNA repair and, 
therefore, lack of normal ATM function in inherited 
AT syndrome results in a pleiotropic clinical 
syndrome characterized not only by a marked 
increase in the risk of cancer but also profound 
hypersensitivity to ionizing radiation. Cells derived 
from patients with AT presents genomic instability, 
loss of normal cell cycle arrest pathways, defects in 
DNA repair and increased sensitivity to radiation. 
These mechanisms indicate the ATM play an 
important role in maintaining genomic integrity and, 
therefore, in the mechanism of cancers 
pathogenesis (10, 11). 
ATM is a gene known to be associated with 
radiosensitivity in the germ line, studies show 
that its inhibition increases the sensitivity of cancer 
cells to radiotherapy, one of the most frequently 
used treatments for different types of  cancer, in 
order to eliminate the cells tumors,  but the 
molecular determinants andclinical response in ATM 
patients are still poorly understood (12). In this 
sense, this narrative review aims to provide an 
overview in order to outline the current 
understanding of the predictive potential of ATM 
gene mutation to respond to the risk of 
radiationtoxicity and radiation therapy, as well as the 
susceptibility to cancer among patients with AT 
mutations. 
 
II. RESULTS AND DISCUSSION 
Structure and functions of ATM 
The ATM gene was first identified in 1995 through 
studies of AT syndrome (13). It locates in the human 
chromosome 11q22-23, includes 66 exons with a 
9168-base pair. ATM is a powerful protein kinase, 
member of the phosphatidyl inositol 3 (PI3K) like 
protein kinase (PIKK) family, that encodes a human 
PI3K serine/threonine PIKK that helps maintain 
genomic integrity (14). This protein is involved in a 
multitude of cellular processes. It has been well 
described that it plays an important role in the 
normal development and activity of body systems, 
including the nervous and imunesystems. It also 
attends to cells in recognizing damaged or broken 
DNA strands. In this context, it plays a central role in 
the repair of DNA double-strand breaks (DSB), which 
can be induced by several mechanisms, including: 
ionizing radiation, chemotherapy drugs, or oxidative 
stress, or even occur during normal physiologic 
events like meiotic recombination or rearrangement 
of antibody genes during B-cell maturation (15, 16). 
It is a consensus within the scientific community that 
ATM has extensive roles in DNA damage response 
signaling, and plays a critical role in the signal 
transduction of cell cycle checkpoint, the repair of 
damaged DNA and the apoptosis(14). Some authors 
report that ATM is a master regulator of DNA damage 
response (17). 
The ATM protein location is predominantly nuclear in 
most cell types (where it exists as a non-covalent 
homodimer) and also in subcellular organelles. This 
form of protein is catalytically inactive in the resting 
state cells, but with DNA damage it is rapidly 
activated and converts to an active monomer from 
that phosphorilates a large number of substrates 
involved in a diverse array of cellular process, like cell 
cycle checkpoints and DNA repair(18). Thus, ATM 
responds locally to specific DNA damage, 
phosphorilating the main substrates involved in DNA 
repair and/or the cell cycle control (14). 
Once activated (when DNA damage is detected), 
ATM phosphorylates a large number of 
downstream effectors, which then phosphorylate its 
own targets. It has been described that there are 
more than 700 targets after DSBs and also that ATM 
modulates networks that are not immediately 
involved in DNA repair, such as the insulin-like 
growth factor or other metabolic and stress-
response pathways (19).The abundance of ATM 
targets are probably a means of coordinating several 
pathways in the event of DNA repair or genomic 
stress (20). 
Considerable progress has been achieved in 
delineating the role of ATM in controlling the cell 
cycle checkpoint, given the large number of 
researches in this field. However, the focus of current 
research is the relationship between ATM and 
signaling pathways in certain events, such as type of 
tumors and sensitivity to radiation/radiation 
treatment in these events, as well as personalized 
pharmacological treatments in AT patients. The 
central question here seems to be what the best 
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therapeutic approach is to be indicated for these 
patients. 
 
III. The role of ATM in damage response induced by 
radiation 
Cell cycle checkpoints are crucial and can improve 
cell expansion and limit mutagenic events after DNA 
damage. It is already known that ATM mediated 
signaling pathways (Figure 1) play an essential role in 
the responses of the checkpoint of the radiation-
induced cell cycle, such as that induced by ionizing 
radiation (21).  
 
Figure 1: Model to explain the role of ATM in DNA damage response. ATM maintains the DNA integrity and, 
consequently, genomic stability, activating multiple cellular functions. A defect in the ATM leads to 
abnormal responses to DNA damage and consequently to cancer susceptibility. 
 
In response to radiation-induced DNA-damage, ATM 
kinases are activated quickly, which in turn triggers 
phosphorylation of their respective downstream 
targets, including p53, kinesin-associated kap-1 
protein (KAP-1), as well as the checkpoint kinases 1 
(CHK1) and 2 (CHK2) (13, 22), two serine/threonine 
protein kinases (Ser/Thr), that play an important role 
in the regulation of the cell cycle and in the 
phosphorylation of p53, which plays an important 
role in the control of the cell cycle and in apoptosis.  
The activation of CHK1 and CHK2 results in 
phosphorylation of Cdc25, leading to sequestration, 
degradation and / or subcellular inhibition (inhibitory 
phosforilation) that normally activates Cdc2 / cyclin 
B at the G2 / M limit (23). CHK2 can also 
phosphorylate p53-Ser20 to bring stabilization of the 
p53 protein after radiation. The activation of p53 by 
ATM, ATR and CHK2 kinases leads to the induction of 
p21 protein, which can directly inhibit the activity of 
the Cdc2 / Cyclin B complex, which governs entry into 
mitosis (22). Additional evidence supports a direct 
role of ATM in other checkpoints of the cell cycle, 
which includes c-Abl, a protein tyrosine kinase, and 
beta-adaptin, an endosomal protein, among others 
(24).  
This activation lead to cell cycle checkpoints, arrests 
and delays in the G1, S, and G2 phases of the cell 
cycle and even allows DNA repair of double-strand 
breaks, both by homologous recombination and by 
non-homologous final union (15, 16). The G1/S 
interface ATM has been shown to play a central role 
in radiation-induced activation of the p53 tumour 
suppressor gene product, since ATM binds to p53 in 
a complex way and activates the molecule in 
response to breaks in DNA. The signaling pathways of 
the radiation-induced cell cycle checkpoint promote 
cell cycle arrest, which, in turn, contributes positively 
to cell survival in response to this event (8, 25). 
Therefore, ATM levels are not altered after exposure 
to ionizing radiation, but ATM kinase activity 
increases after exposure several times (21).  
Cells of patients with AT syndrome fail to show initial 
delay at several checkpoints of the cell cycle after 
irradiation. In addition, a defect in the induction of 
p53 by ionizing radiation was evident in these 
patients. In this sense, the ATM gene mutation leads 
to the functional and structural alteration of the 
ATM protein in the these patients, leading to the 
occurrence of abnormalities in the cell cycle 
checkpoint and DNA damage repair, leading to an 
increase in sensitivity to apoptosis. The ATM gene 
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mutated production the human genetic disorder AT 
is a 350 kDa protein that plays a central role in the 
regulation of several cellular processes. Therefore, 
defects are observed at all cell cycle checkpoints in 
post-irradiation AT cells (26, 27).  
 It is likely that environmental radiation exposure 
may have a greater effect on certain ATM genotypes 
/ variants and may induce different modifications in 
cellular responses in these patients. In this case, the 
importance of radiation exposure as a risk factor 
must be examined in epidemiological analyses 
stratified by genotype (28).  
 
ATM and Radiosensititity 
ATM is described as one of the main regulators of the 
cellular response to radiation-induced DNA damage 
and a key determinant of radiosensitivity (28). This 
evidence has been demonstrated by several previous 
studies that have shown a leading role for ATM 
kinase in the regulation of cancer cell radioresistance 
(29, 32) 
On the other side, radiation therapy is an approach 
to cancer treatment that has unquestionably 
significantly improved the local control of the disease 
and the overall survival of cancer patient. In general, 
radiation hinders the growth of cancer cells by 
inducing cytotoxicity, caused mainly by DNA damage 
(29). 
DNA damage induced by ionizing radiation can 
significantly affect whether a cell will proliferate, 
differentiate, become senescent, or go into 
apoptosis (30, 31). In general cellular properties 
(such as cell type and tissue of origin) determined the 
DNA damage associated cell-fate decisions (32). Even 
the physiological properties of the cells, including the 
ability to detect, repair, and tolerate DNA damage, 
are likely to be important determinants of fate when 
cells are exposed to to varying degrees of DNA 
damage (33).  
In addition, the amount and quality of DNA damage 
also affects these decisions about the fate of cells. 
Thus, the dose rate of sparingly ionizing radiation is 
particularly important, since lower dose rates 
produce smaller biological effects, even when the 
total dose is kept constant (34).Hickson and cols (24) 
confirm these data and suggest that inhibition of 
ATM should radiosensitize tumors. They showed that 
fibroblasts and tumor cells are radiosensitized to X-
ray radiatiotherapy (XRT) in culture by 
pharmacological ATM inhibition, or by ATM mutation 
and deletions (35). However, caution is needed when 
using this strategy clinically, due to the possibility 
that normal tissues may also be sensitized as well. 
This reluctance is well founded, as it is based on the 
previous dire response of patients with AT to XRT 
already described. 
Thus, cells harboring loss-of 
function ATM deficiencies demonstrate 
extreme radio sensitivity. Further, AT syndrome is 
often referred to as a genome instability or DNA 
damage response syndrome. For this reason, the 
efficiency of radiotherapy has been considered very 
limited in patients with biallelic mutations or 
deletions of ATM due to its toxic effect on normal 
tissue (36).  
Cao and cols (33) have been demonstrated a critical 
role for the ATM tumor protein p53 (TP53)/p21 
pathway in the regulation of DNA-damage-
associated cell fate. Cultured mouse cells were 
exposed to various amounts and qualities of 137Cs γ-
irradiation and then and then the effects of this 
irradiation on different types of human cells were 
monitored. The researchers showed that inhibition 
of ATM/TP53/p21 complex change the responses to 
DNA damage, leading to micronucleus formation in 
chronically irradiated cells, the measure of which 
assesses genomic instability. In addition, the study 
clearly demonstrated that the ATM/TP53/p21 
pathway regulates the relationship between DNA-
damage tolerance and response when cells were 
exposed to chronic γ-irradiation and that this 
decision depended on the dose rate and the cell type. 
The TP53 pathway was a critical component of 
cellular responses to chronic γ-irradiation, which 
were triggered by the rate of DNA damage. 
A recently published study evaluated whether 
radiation therapy affects contralateral breast cancer 
risk in women with ATM pathogenic germline 
variants (among others) in breast cancer. This study 
described that rare ATM missense variants, currently 
not identified as pathogenic, were associated with 
risk of radiotherapy(37). 
 It is very important to identify the critical 
determinants of radioresistance and to develop safe 
and effective tumor radiosensitizers, especially 
considering patients with ATM gene deficiencies. 
Thus, taking these processes into account, there is 
still  an extensive field of research for the 
development of ATM inhibitors (ATMi) as anticancer 
agents (38). 
 
ATM mutations and malignancy risk 
The ATM gene is mutated in the autosomal recessive 
disorder, AT syndrome, characterized by an 
increased risk of susceptibility to cancer throughout 
life (39, 40), and may be related to the 
radiosensitivity, resulting in chromosomal and 
chromatid breaks.  
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The types tumors are diverse in patients with AT. 
Previous data indicate a high incidence of lymphoid 
neoplasms, most notably T-cell acute lymphoblastic 
leukemias. Recently, B-cell non-Hodgkin´s lymphoma 
and Hodgkin´s lymphoma was also reported to be 
more frequent than initially recognized. Patients 
with AT also develop carcinoma, but less frequently 
and at an older age than lymphoid cancers (40-42).  
Another category, AT mutation carriers, are generally 
healthy individuals who have a mutated copy of 
the ATM gene, such as the parents or other blood 
relatives of a person with AT syndrome. However, a 
systematic meta-analysis found that patients with 
ATM mutation have a short lifespan due to cancer 
(breast and gastrointestinal tract) and ischemic heart 
disease (43). 
More than 400 disease-related mutations have been 
described in ATM gene, which may be due to 
mutations in a homozygous or compound 
heterozygous germline. ATM mutations identified in 
AT families can be divided in three categories; 
truncating mutations, mutations that lead to some 
expression of mutant protein that does not have 
kinase activity and missense mutations with reduced 
kinase activity(44). Approximately 70% of the 
disease-related mutations result in the production of 
truncated protein (45). 
ATM carriers who are heterozygous for ATM gene 
variants are often asymptomatic and largely 
considered healthy carriers. Despite this, it has been 
described that they are more sensitive to ionizing 
radiation and susceptible to ischemic heart disease, 
diabetes, and cancer, specially breast cancer, and 
that of digestive tract, lung and lymphoid origin (46, 
47). 
Monoallelic ATM mutation carriers are also at risk of 
malignancy, particularly breast cancers, and many 
association studies have been conducted on breast 
cancer susceptibility. Initially, epidemiological 
studies on relatives of AT patients revealed a two to 
five-fold increase in the risk of breast cancer for 
female obligate ATM carriers (20, 48, 49).  
ATM mutations are associated with an increase of 
approximately two to to three times the risk of breast 
cancer, however, for patients with a familial history 
of the disease, risk estimates increase even 
more,which is probably due to other risk increasing 
variants in the families (50, 51).The increased risk of 
breast cancer in patients with ATM was confirmed by 
direct ATM sequencing in breast cancer cases 
compared to controls(49). ATM is also considered a 
moderate-penetrance cancer susceptibility gene 
in BRCA1/2-negative patients with familial early-
onset breast cancer (52). 
Another recently published study (53) evaluated 
deleterious germline mutations in ATM by PCR-
Sanger sequencing 7657 in BRCA1/2 negative breast 
cancer patients and founded 31 pathogenic 
mutations in the ATM gene across 30 carriers. The 
ATM mutation rate was 0.4% (30/7.657). Those 
patients were significantly more likely to have family 
history of breast and/or ovarian cancer (26.7% in 
carriers vs. 8.6% in non carriers). Another study 
corroborates these data when using the multigenic 
panel by next generation sequencing method to 
identify that ATM was mutant in non-BRCA1/2 
patients with hereditary risk of breast cancer (54). 
Next-generation sequencing has led to the recent 
discovery that pathogenic ATM variants are often 
identified in patients with pancreatic ductal 
adenocarcinoma with and without a family history of 
the disease. In addition, it was described that the loss 
of ATM was also a frequent somatic event in the 
development of these type of cancer (55). ATM was 
recently described using a complete exome 
sequencing technique as one of the most frequently 
mutated germline genes in aggressive prostate 
cancer (56). Another molecular method was used to 
evaluate the relation between ATM polymorphism 
and gastric cancer in the Chinese population. The 
study found that the ATM polymorphism was related 
to increased susceptibility and worse prognosis (57). 
Along with mutations associated with AT , several 
ATM examinations in cancer patients have identified 
missense ATM variants, particularly amino acid 
substitutions that are not expected to be associated 
with AT (58). However, discrimination of these ATM 
variants from ATM polymorphisms and their 
contribution to health risks is still controversial (59).  
A national cohort study carried out in the registry of 
the French National Reference Center for Primary 
Immune Deficiencies (CEREDIH), conducted by 
Suarez and cols (40) evaluated retrospectively the 
incidence of cancer in 279 patients with AT 
syndrome. The follow-up of patients with AT with 
malignant neoplasms was 13.9 years and the 
incidence of malignancy was 24.7% among them 
(1,571 events per 100,000 person-years) and did not 
vary across decades. The median age at diagnosis of 
malignancy of any type was 12.5 years and differed 
significantly across the groups of tumors (an average 
age of onset of Hodgkin´s lymphoma is 10.6 years old 
and carcinomas, 31 years old). Lymphoid neoplasms, 
particularly acute lymphoblastic leukemia, Hodgkin´s 
lymphoma, and non-Hodgkin´s lymphoma, 
represented the majority of cancers. The study (40) 
showed that the cumulative incidence of cancer was 
10.4% at 10 years, 22.6% at 20 years, 29.9% at 30 
years, and 38.2% at 40 years. By age 10 years, 1.9% 
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of patients had developed lymphoblastic leukemia, 
2.3% Hodgkin´s lymphoma, and 6.2% non-Hodgkin´s 
lymphoma. At 20 years of age, 3.5% of patients 
developed acute lymphoblastic leukemia, 5.5% 
Hodgkin´s lymphoma, and 13.6% non-Hodgkin´s 
lymphoma. No patient developed acute 
lymphoblastic leukemia or Hodgkin´s lymphoma 
after age 20 years. At age 30, 17.6% of patients 
developed non-Hodgkin´s lymphoma, 2.6% T-PLL and 
0.8% a solid tumor. At 40 years of age, 20% of 
patients developed non-Hodgkin´s lymphoma and 
6.6% a solid tumor (40). This study also showed that 
solid cancers (such as breast, gastric, liver, and 
thyroid) comprised mostly carcinomas.  
The patient's family and personal history is important 
for identifying and diagnosing tumors. In a 
retrospective study of 279 patients with AT 
syndrome, 69 had cancer and most were 
hematological cancers, including the majority as 38 
cases of non-Hodgkin's lymphoma (60)  
Although the precise mechanisms of malignancy in 
AT are not fully understood, it is considered to be 
primarily related to the role of ATM in maintaining 
genomic stability. However, the exact contributions 
of the various ATM functions, the immunodeficiency 
associated with AT and possible extrinsic factors 
remain unclear until now. Immunodeficiency 
associated with AT is variable, and its causal 




Considering the unusual radiosensitive phenotype of 
cells from AT patients, ATM has been the focus of 
intense scrutiny for the past two decades. In order to 
improve the efficacy of radiation therapy in AT 
carriers, it is necessary a better understanding of the 
signaling network that drives ATM mutated cell to be 
cancerous and then to overcome radiation-induced 
cytotoxicity.  
The treatment of ATM mutations in cancer patients 
is challenging, because the impact of antineoplastic 
treatment on response and toxicity is not well 
established. Survival after cancer is considered short 
in TA patients, but long-term remissions are possible. 
The risk of second neoplasms is still not well 
established in these patients, and there is no 
consensus in the scientific community. Recognition 
of clinical and biological heterogeneity in the ATM 
mutation, both for AT syndrome and for AT carriers, 
is thought to be at least in part associated with the 
type of ATM mutations, and patients with loss of 
function mutations appear to have different 
susceptibility cancer and different survival rates.  
The identification of patients with a mutable or 
pathogenic ATM variant of the germ line and, 
therefore, a greater susceptibility to the 
development of some types of cancer, is essential for 
the early detection that is advocated in improving 
patient care, detecting cancer before metastases, 
contributing to the improvement of the patient's 
prognosis and life expectancy. 
Despite the great efforts of the scientific community, 
we can conclude that there is a great gap with regard 
to the therapeutic conduct of ATM patients. Well-
designed studies are still needed to contribute to a 
better understanding of cancer susceptibility in AT 
patients, and its relationship with radio sensitization, 
in addition to ATM-mediated signaling, to cause cells 
to stop the cycle and start DNA repair The analysis of 
these genotypes can eventually be applied clinically 
to determine treatment modalities in affected 
patients.. Taken together, targeting ATM in 
association with another genetic panel can be a 
promising strategy for cancer treatment.  
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